Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Praecis Puts Brakes On Plenaxis, Explores Strategic Financing Options

This article was originally published in The Pink Sheet Daily

Executive Summary

Company will record $7.5 mil. in charges after announcing it will not enter a licensing or sale transaction for the prostate cancer therapy.

You may also be interested in...



GSK Shopping Spree Continues With Praecis Acquisition

Latest deal could bring GSK’s total price tag for December to almost $4 billion.

Future BIO Global Efforts Include International Relations, Greenwood Says

HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel